scispace - formally typeset
O

Olympia E. Anastasiou

Researcher at University of Duisburg-Essen

Publications -  63
Citations -  1193

Olympia E. Anastasiou is an academic researcher from University of Duisburg-Essen. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 11, co-authored 51 publications receiving 591 citations.

Papers
More filters
Journal ArticleDOI

SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients.

TL;DR: The overall seroprevalence of SARS-CoV-2 in healthcare workers of a tertiary hospital in Germany is low and the data indicate that the local hygiene standard might be effective.
Journal ArticleDOI

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).

TL;DR: In this paper, the effect of established mRNA-based SARS-CoV-2 vaccines have been evaluated for solid organ transplant patients (SOT) since they are known to have poor responses after vaccination.
Journal ArticleDOI

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation.

TL;DR: A predominant expansion of PMN-MDSC in solid tumors that exceeds expansion in chronic infection and inflammation is revealed and provides improved technical protocols and workflows for the multi-center analysis of circulating human MDSC subsets.
Journal ArticleDOI

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis

TL;DR: In this article, the authors measured humoral immune responses in 72 hemodialysis patients after standard vaccination with two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech).
Journal ArticleDOI

Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients-A Single-Center Experience.

TL;DR: In this paper, the authors analyzed immunogenicity in 43 liver transplant recipients in a median of 15 days (IQR, 12-24) after receiving two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol, and compared these results to a control group consisting of 20 healthcare workers.